BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Congratulates Dirk Görlich on $1.4M World Laureates Association Prize in Life Sciences

Nov 15, 2022

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today congratulated its co-lead scientific research collaborator Professor Dr. Dirk Görlich, director at the Max Planck Institute for Multidisciplinary Sciences (“MPI”), on being awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine for his seminal work describing protein transport within the cell. “On behalf of BiondVax’s team, I wish to offer my sincere congratulations to Dirk on being awarded the inaugural WLA Prize in Life Sciences. The award signals recognition and appreciation of his important research achievements and deep scientific acumen,” said Amir Reichman, BiondVax’s CEO. “His expertise extends to the unique and innovative NanoAb candidates being developed under our collaboration. We look forward to forging ahead together with Dirk, Matthias and their teams as we strive to bring a pipeline of NanoAb therapies that exhibit significant competitive advantages for conditions underserved by currently approved therapeutics.”

To view the full press release, visit https://ibn.fm/xxZra

About BiondVax Pharmaceuticals Ltd.

BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven country, 12,400 participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

More News

Klay Thompson embraces new challenge in 1st season with Heat

Sep 29, 2026

Klay Thompson embraces new challenge in 1st season with Heat

BOCA RATON, Florida — Klay Thompson's legacy was secured long ago. He was part of four championship teams with Golden State, is one of the best shooters the NBA has ever seen, holds the league's single-game record for 3-pointers made and is surely headed to the Basketball Hall of Fame. He wants more. And that's why the Miami Heat pounced quickly when the 36-year-old Thompson was bought out by the Dallas Mavericks over the summer. They're convinced that Thompson still has much to offer and will flourish on a new-look Heat with Giannis Antetokounmpo teaming up with Bam Adebayo. “I want to be able to look back one day and say I gave it everything I had,” Thompson said Tuesday after his first training camp practice with the Heat, held at Florida Atlantic University. “And I think being with the Heat, it gives me that opportunity. They’re wholly committed to winning. And I've said this before: winning trumps any individual performance I’ve ever had. To be a part of a season of chasing that goal is special.” Thompson's resume is almost beyond compare. He's made at least 200 3-pointers in a season 11 times; that's second-most in NBA history behind his former Golden State teammate and “Splash Brother” Stephen Curry, who has 12 such seasons. With 2,899 career 3s, he's only 74 behind former Heat guard Ray Allen for No. 3 on the all-time list — and 101 away from the 3,000-made milestone, something only Curry and James Harden have surpassed. And here's one that not everyone might expect: Thompson — even without being a full-time starter — is also the only player in the NBA with at least 200 made 3s in each of the last four seasons. He made 202 last season in Dallas, despite playing a career-low 21.7 minutes per game. “What Klay’s done in this league, I think should be celebrated and respected in our locker room — which it is," Heat coach Erik Spoelstra said. “We can take from those experiences. And I think also he can be excited about this possibility of a new experience to be able to create hopefully something similar, but in a different way and a different locker room and different culture.” The general perception is that Thompson will play a role similar to what Allen played in the Heat era that featured LeBron James, Dwyane Wade and Chris Bosh. If defenders help off Thompson, it's likely that they'll pay by leaving one of the best shooters in the world — someone who doesn't need much time to get a shot off — open. And if they don't help off him, that's just going to make life easier for Adebayo, Antetokounmpo and everyone else in Heat colors. “We've got former champions,” Heat guard Davion Mitchell said. “They know what it takes to win.” Thompson is about to enter his 14th season, not counting two missed because of injury. He’s a career 41% shooter from beyond the arc, is a five-time All-Star and has made at least 10 3s in a game on nine different occasions. And this summer, in a workout that led to a viral video from famed shooting coach Chris Brickley, Thompson made 72 consecutive shots from beyond the arc. “It’s a good feeling,” Thompson said, “but I would rather make 10 in a row in an NBA game.” The Heat would like to see that as well. They always have championship aspirations, but the changes to the roster this summer — adding Antetokounmpo, another knockdown shooter in Tim Hardaway Jr., Bobby Portis and Thompson, among others — make those hopes quite legitimate, even with Miami competing against a loaded Eastern Conference. “I hopefully one day get the chance to be in the Hall, but before that I still feel like I have so much left to give this game,” Thompson said. “The records even matter to me. I want to still climb up the record books because I’m such a basketball junkie. I grew up watching Ray Allen, Reggie Miller, and those guys inspire me to shoot the ball every single day. And the fact that I have a chance to pass Ray in a Heat uniform, that gives me so much motivation to keep going.”

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.